Cardiology

Ramin Artang MD, FACC, FASE, FASNC, RPVI

Assistant ProfessorArtang
Cardiology, Division of Internal Medicine

Academic Office:
Department of Internal Medicine
982265 Nebraska Medical Center
Omaha, NE 68192-2265
(402)-559-5151

Education:
Univeristy of Copenhagen (Copenhagen, Denmark)
Doctorate of Philosophy, 2001
Doctor of Medicine, 1994

Marshfield Clinic (Marshfield, WI)
Resident - Internal Medicine, 2001

Medical College of Wisconsin (Milwaukee, WI)  
Cardiovascular Disease Fellowship, 2004 - 2007

Board Certifications:
Cardiolovascular Disease, Internal Medicine, Echocardiography, Cardiac CT angiography, Nuclear Cardiology, Vascular Medicine, Vascular Physician Interpreter

Clinical Expertise:
Echocardiography, Cardiac CT Angiography, Nuclear Cardiolgoy and Invasive Cardiology

Research Expertise:
Novel antithrombotics. Platelets function assessment and methodology, Coronary Artery Disease, Multimodality assessment of Right ventricular Function, Left atrial volume, and Diastolic Dysfunction, Chemotherapy induced cardiomyopathy

Selected Publications:

  1. Artang R, Jurgensen G, Frandsen NJ, Abildgaard U, Nielsen JD, Rezkalla S. Abciximab Upregulates the Number of Glycoprotein IIb/IIIa Receptors In Vivo". Journal ofAmericanCollegeof Cardiology. 2003 Mar 19;41(6), Suppl. A, Abstract p78A.
  2. Artang R, Jurgensen G, Frandsen NJ, Nielsen JD. Thrombelastography capable of Monitoring inhibition by Glycoprotein IIb/IIIa inhibitors. Blood 2002, Vol. 100 Suppl. Abstract # 3972.
  3. Artang R , Jurgensen G, Frandsen NJ, Nielsen JD. Clopidogrel enhances the Platelet inhibitory effect of eptifibatide. Blood 2002, Vol. 100 Suppl. Abstract # 3973.
  4. Artang R, Jürgensen GW, Frandsen NJ, Nielsen JD. Increase in number of fibrinogen receptors by Glycoprotein IIb/IIIa inhibitors. European Heart Journal Vol 4, Abstr. Suppl. August 2002, p 494 Abstract # 2578.
  5. Artang R, Jensen E, Frandsen NJ , Pedersen F, Nielsen JD. Association of Risk Factors of Coronary Artery Disease and Clot Strength. European Heart Journal Vol 4, Abstr. Suppl. August 2002, p 566 Abstract # 2827.
  6. Artang R, Jurgensen G, Frandsen NJ, Abildgaard U, Nielsen JD. Comparison of Thrombelastography and aggregometry in Monitoring Glycoprotein IIb/IIIa inhibition. Arterioscler Thromb Vasc Biol 2002, Abstract Suppl. # P180.
  7. Artang R, Jensen E, Pedersen F, Frandsen NJ , Nielsen JD. Assessment of Antithrombotic effect of Low Molecular Weight Heparin by Thrombelastography in Cardiac Patients. Thrombosis and Haemostasis, Supplement July 2001, Abstract (ISSN 0340-6245).
  8. Artang R, Jensen E, Pedersen F,FrandsenNJ. Clot Strength in Ischemic Heart Disease. Scandinavian Cardiovascular Journal 1999; 33: suppl. 51, Abstract p56.
  9. Artang R, Hermann L, Migrino RQ, Woods TD. Left Atrial Volume Measurement by 3 Dimensional Echocardiography: A Practical Alternative to the Area-Length Method. J Am Soc Echocardiogr 2007; 20: 560, P1-12. Abstract.
  10. Artang R, Khadim G, Dieter RS. Late Thrombosis in Drug-Eluting Stents: Meta-Analysis
    of All Published Case Reports. J Am Col Cardiol 2007;49; Suppl 1B, 44B, Abstract.
  11. Artang R, Jensen E, Pedersen F,FrandsenNJ. Thrombelastography in Healthy volunteers, patients with Stable angina and acute chest pain. Thrombosis Research 2000, 97; 499-503.
  12. Artang R, Vidaillet H. Alternatives to warfarin for Thromboembolism Prophylaxis in Nonrheumatic Atrial Fibrillation. J Interv Card Electrophysiol 2004, 10; Suppl. 1, 33-44.
  13. Artang R, Dieter RS, Analysis of 36 reported cases of Late Thrombosis in Drug-eluting stents placed in Coronary Arteries. Am J Cardiol 2007, 99:1039-43.
  14. Artang R, Migrino RQ, Hermann L, Bowers M, Woods TD. Left Atrial Volume Measurement with Automated Border Detection by 3-Dimensional Echocardiography: Comparison with Magnetic Resonance Imaging. Cardiovascular Ultrasound 2009, 7:16.
  15. Artang R, Frandsen NJ, Dalsgaard Nielsen J. Application of Basic and Composite Thrombelastography parameters in Monitoring of the Antithrombotic Effect of the Low Molecular Weight Heparin Dalteparin: An in vivo study. Thrombosis Journal 2009, 7:14.
  16. Artang R, Rome E, Vidaillet H. Dabigatran and Myocardial Infarction, Drug or Class effect. Meta-Analysis of Randomized Trials with Oral Direct Thrombin Inhibitors. J Am Coll Cardiol. 2012;59(13s1):E571-E571.